Forward Pharma A/S (NASDAQ:FWP) Short Interest Update

Forward Pharma A/S (NASDAQ:FWPGet Rating) was the target of a significant drop in short interest during the month of April. As of April 30th, there was short interest totalling 34,900 shares, a drop of 20.5% from the April 15th total of 43,900 shares. Based on an average trading volume of 9,300 shares, the short-interest ratio is presently 3.8 days.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Morgan Stanley raised its holdings in shares of Forward Pharma A/S by 1.2% during the 2nd quarter. Morgan Stanley now owns 181,799 shares of the biotechnology company’s stock valued at $1,563,000 after buying an additional 2,099 shares during the period. Goldman Sachs Group Inc. acquired a new stake in Forward Pharma A/S in the third quarter valued at approximately $105,000. Renaissance Technologies LLC purchased a new stake in shares of Forward Pharma A/S during the third quarter valued at approximately $597,000. Finally, Citadel Advisors LLC acquired a new position in shares of Forward Pharma A/S during the third quarter worth $141,000. 10.41% of the stock is owned by institutional investors.

Separately, began coverage on shares of Forward Pharma A/S in a research report on Friday. They set a “sell” rating on the stock.

Shares of FWP stock opened at $5.41 on Monday. Forward Pharma A/S has a one year low of $4.86 and a one year high of $20.31. The company has a 50 day moving average price of $5.70 and a 200 day moving average price of $5.86.

About Forward Pharma A/S (Get Rating)

Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.

Read More

Receive News & Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related companies with's FREE daily email newsletter.